Intravenous platelet blockade with cangrelor during PCI

The New England Journal of Medicine
Deepak L BhattCHAMPION PLATFORM Investigators

Abstract

Intravenous cangrelor, a rapid-acting, reversible adenosine diphosphate (ADP) receptor antagonist, might reduce ischemic events during percutaneous coronary intervention (PCI). In this double-blind, placebo-controlled study, we randomly assigned 5362 patients who had not been treated with clopidogrel to receive either cangrelor or placebo at the time of PCI, followed by 600 mg of clopidogrel. The primary end point was a composite of death, myocardial infarction, or ischemia-driven revascularization at 48 hours. Enrollment was stopped when an interim analysis concluded that the trial would be unlikely to show superiority for the primary end point. The primary end point occurred in 185 of 2654 patients receiving cangrelor (7.0%) and in 210 of 2641 patients receiving placebo (8.0%) (odds ratio in the cangrelor group, 0.87; 95% confidence interval [CI], 0.71 to 1.07; P=0.17) (modified intention-to-treat population adjusted for missing data). In the cangrelor group, as compared with the placebo group, two prespecified secondary end points were significantly reduced at 48 hours: the rate of stent thrombosis, from 0.6% to 0.2% (odds ratio, 0.31; 95% CI, 0.11 to 0.85; P=0.02), and the rate of death from any cause, from 0.7% to 0.2% (od...Continue Reading

References

Aug 25, 2001·The New England Journal of Medicine·S YusufUNKNOWN Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Aug 25, 2001·Lancet·S R MehtaUNKNOWN Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators
Jan 5, 2002·Journal of the American College of Cardiology·Deepak L BhattEric J Topol
Nov 19, 2002·JAMA : the Journal of the American Medical Association·Steven R SteinhublUNKNOWN CREDO Investigators. Clopidogrel for the Reduction of Events During Observation
Mar 11, 2005·The New England Journal of Medicine·Marc S SabatineUNKNOWN CLARITY-TIMI 28 Investigators
Sep 7, 2005·JAMA : the Journal of the American Medical Association·Marc S SabatineUNKNOWN Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators
Nov 25, 2006·The New England Journal of Medicine·Gregg W StoneUNKNOWN ACUITY Investigators
May 15, 2007·Circulation Research·Telly A Meadows, Deepak L Bhatt
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Nov 6, 2007·The New England Journal of Medicine·Deepak L Bhatt
Feb 4, 2009·Circulation·Cyrus MehtaJames H Ware
May 8, 2009·The New England Journal of Medicine·Gregg W StoneUNKNOWN HORIZONS-AMI Trial Investigators
Jul 17, 2009·The New England Journal of Medicine·Deepak L Bhatt
Sep 1, 2009·The New England Journal of Medicine·Albert Schömig
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén

❮ Previous
Next ❯

Citations

Jan 19, 2012·JAMA : the Journal of the American Medical Association·Dominick J AngiolilloUNKNOWN BRIDGE Investigators
May 15, 2010·Journal of Thrombosis and Thrombolysis·Martin Moser, Christoph Bode
Jun 28, 2011·Journal of Thrombosis and Thrombolysis·Aldona KubicaAleksander Goch
Nov 28, 2012·Journal of Thrombosis and Thrombolysis·José L FerreiroDominick J Angiolillo
Jun 29, 2011·Purinergic Signalling·Stephen O'ConnorJean-Philippe Collet
Feb 24, 2010·Internal and Emergency Medicine·Marco Cattaneo, Gian Marco Podda
Nov 22, 2011·Current Atherosclerosis Reports·Luke KimDmitriy N Feldman
Sep 16, 2010·Current Treatment Options in Cardiovascular Medicine·Marc Bonaca, Robert P Giugliano
Oct 12, 2012·International Journal of Hematology·Fatemeh Moheimani, Denise E Jackson
Feb 14, 2013·Journal of Cardiovascular Translational Research·Fabiana RolliniDominick J Angiolillo
Apr 25, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Dominick J Angiolillo, José Luis Ferreiro
Jul 4, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Amitabh Prakash
Feb 25, 2010·Nature Reviews. Cardiology·David P Faxon
Jun 30, 2010·Nature Reviews. Cardiology·Jeremy S PaikinJack Hirsh
Jun 3, 2010·Nature Reviews. Cardiology·Kumaran Kolandaivelu, Deepak L Bhatt
Jul 14, 2011·Nature Reviews. Cardiology·Omair Yousuf, Deepak L Bhatt
Jan 16, 2013·Nature Reviews. Cardiology·Kush Agrawal, Deepak L Bhatt
Apr 24, 2013·Nature Reviews. Cardiology·Robert F Storey
Mar 20, 2010·The New England Journal of Medicine·Neil Ruparelia, Nicos Spyrou
Nov 17, 2009·The New England Journal of Medicine·Adnan Kastrati, Gjin Ndrepepa
Mar 12, 2013·The New England Journal of Medicine·Richard A Lange, L David Hillis
Sep 8, 2010·The New England Journal of Medicine·Shamir R MehtaSalim Yusuf
Mar 12, 2013·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHAMPION PHOENIX Investigators
Feb 4, 2011·The New England Journal of Medicine·Abhiram Prasad, Joerg Herrmann
Mar 15, 2011·The American Journal of Bioethics : AJOB·Edward L Korn, Boris Freidlin
Dec 22, 2010·British Journal of Anaesthesia·P Barash, S Akhtar
Dec 18, 2013·British Journal of Anaesthesia·A D Oprea, W M Popescu
Apr 12, 2011·Thrombosis and Haemostasis·Robert F Storey
Dec 14, 2011·Hematology·Alan D Michelson
Mar 4, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Dominick J AngiolilloShinya Goto
Sep 22, 2010·Drug Design, Development and Therapy·Son V PhamPhuong-Anh T Pham
Jul 14, 2012·Journal of Blood Medicine·Jennifer Yeung, Michael Holinstat
Jul 27, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·David Vivas, Dominick J Angiolillo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.